Project Grant R21CA309321
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $406K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
- Federal Project Grant Summary Cincinnati Children's Hospital Medical Center received a $1.48M Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 1, 2025, with completion scheduled for August 31, 2030. The grant funds the development and efficacy evaluation of SUMMIT (Supporting Medication Management with Individualized Treatment), a tailored medication adherence-promotion intervention designed...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 11, 2025 through August 31, 2030. The project, "Targeting Polyamine Metabolism in Relapsed Acute Myeloid Leukemia Stem Cells," focuses on fundamental research to understand and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs). The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $639,295 Project Grant to the Research Institute at Nationwide Children's Hospital on May 8, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). This five-year award, with performance through April 30, 2031, supports research investigating the molecular mechanisms of FET::ETS oncogenic fusion proteins, specifically examining how these proteins alter DNA binding and chromatin regulation in cancer....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $608,558 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Research Institute at Nationwide Children's Hospital, effective April 2, 2026, through March 31, 2031. This fundamental cancer research initiative aims to advance understanding of high-risk neuroblastoma through the development of clinically relevant immunocompetent mouse models and the identification of metabolic vulnerabilities that can...
- Federal Grant Award Summary Ann & Robert H Lurie Children's Hospital of Chicago received a $651,859 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 19, 2025, with an ultimate completion date of August 31, 2030. The grant supports "The AYA Oncology Self-Care Movement (#AYAOSM)," an influencer-driven social media intervention designed to improve oral chemotherapy adherence among adolescents...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Project Grant Award Summary Children's Hospital Los Angeles received an $8.47 million Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded September 10, 2025, with a completion date of August 31, 2029. The grant funds a patient navigation intervention designed to improve transition success among multiply disadvantaged young adult survivors of childhood cancer (CCS). The project addresses a critical gap in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The MGH Institute of Health Professions, Inc. a Project Grant of $696,498 under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention designed to improve functional recovery and participation in life activities among breast cancer survivors. The research, spanning from May 1, 2026, through April 30, 2031, will systematically develop an evidence-based intervention...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a Project Grant totaling $192,564 under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. This award supports the development of chimeric antigen receptor (CAR) modified natural killer (NK) cell-based immunotherapy for the treatment of pediatric solid tumors. The research aims to advance NK cell engineering as a safer and more effective...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...